The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
On September 15, 2026, Recursion Pharmaceuticals amended its long-term data and AI collaboration with Tempus AI, extending the master agreement term from five to six years and waiving its prior right to terminate for convenience. The amendment lowers Recursion’s annual license fees to $14 million payable on the third, fourth, and fifth anniversaries, with at least $4 million in cash each year and the balance potentially in Class A common stock or cash, while also reducing the total de-identified records it can access.
On the same date, Recursion entered into a two-year RNA Foundation Model License Agreement granting Tempus a non-exclusive license to use Recursion’s TxFM RNA sequencing model in oncology for diagnostic, clinical, and internal R&D applications. Tempus will pay Recursion $12 million in two installments and supply de-identified pathology records with linked clinical data, deepening the data and technology partnership and underscoring Recursion’s strategy to monetize its RNA model while reinforcing Tempus’s oncology capabilities.
The most recent analyst rating on (RXRX) stock is a Hold
with a $5.30 price target.
To see the full list of analyst forecasts on Recursion Pharmaceuticals stock,
see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
The score is held back primarily by weak current financial performance—large ongoing losses, negative margins, and substantial operating/free cash flow burn. Offsetting that, the latest earnings call showed meaningful cost discipline, strong partnership validation and cash inflows, and tangible pipeline progress, while technical indicators point to improving momentum. Valuation remains hard to justify on earnings given ongoing losses and no dividend support.
To see Spark’s full report on RXRX stock,
click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a biotechnology company that applies advanced computational and RNA sequencing models to drug discovery, leveraging large-scale multimodal data to identify and develop new therapeutics. Its collaboration with data and AI partners positions the company at the intersection of biopharma and technology, with a particular focus on using foundational RNA models to accelerate research in areas such as oncology and other complex diseases.
Average Trading Volume: 19,108,635
Technical Sentiment Signal: Sell
Current Market Cap: $2.05B
See more data about RXRX stock on TipRanks’ Stock Analysis page.
Trending Articles:
This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.


